GlassScriptPhysician profile
Michael A Jennings
NPI 1528029170
$1,974.17
in general payments reported to CMS, 2019-2025
29 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $116 · 2021: $160 · 2022: $258 · 2023: $282 · 2024: $499 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.78 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $705.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $244.33 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $217.82 | 2021-2025 | |
| Amgen INC. | $134.17 | 2019-2022 | |
| Novo Nordisk INC | $104.96 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $61.82 | 2024-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $58.18 | 2020-2023 | Belsomra |
| Xeris Pharmaceuticals, INC. | $46.56 | 2023-2024 | Keveyis |
| Amarin Pharma, INC. | $40.63 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.76 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.32 | 2025 | |
| Lilly USA, LLC | $29.63 | 2022-2024 | Mounjaro |
| Allergan, INC. | $22.87 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $22.78 | 2020-2021 | |
| Abiomed | $19.88 | 2024 | Impella |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.76 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $16.24 | 2020 | |
| Mallinckrodt Hospital Products INC. | $14.38 | 2025 | Acthar |
| Ultragenyx Pharmaceutical INC. | $14.30 | 2021 | |
| Abbott Laboratories | $13.81 | 2022 | |
| Genzyme Corporation | $13.64 | 2023 | |
| Impel Pharmaceuticals INC. | $13.24 | 2023 | Trudhesa |
| Hologic Sales and Service, LLC | $13.20 | 2021 | |
| Mylan Specialty L.P. | $13.13 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.56 | 2020 | |
| Vbi Vaccine (Delaware) INC. | $11.33 | 2022 | |
| Sanofi Pasteur INC. | $11.32 | 2019 | |
| Glaxosmithkline, LLC. | $11.12 | 2021 | |
| Eisai INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.